Pushing the Limits: How XCell® ATF Hits 200M+ Cells/mL Across Modalities

Published on Repligen Poster, Bioprocessing Summit (July 2023)

With biologics becoming more complex and global manufacturing capacity under pressure, process intensification is no longer optional. This poster highlights XCell® ATF's wide adoption in upstream bioprocessing, achieving >200 million cells/mL with CHO and up to 350 million cells/mL with SF9. Used in over 500 global sites and 40+ commercial processes, the technology has been applied across mAbs, plasmid DNA, vaccines, and even cultivated food. Whether intensifying N-1, N, or harvest steps, XCell® ATF helps reduce cost of goods, facility size, and process bottlenecks while boosting yield 3–5×.

Read the full poster from Repligen:

👉 Disruptive Technologies Transforming Upstream Process Intensification (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.